Vault-13

Aquilo Capital Management, LLC

SAN FRANCISCO, CA · CIK 1591986 · 13F filing filed 2020-08-14

No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.

$272.0m reported value +51.8% vs Q1 2020
13positions
92.7%in top 10
2 new 7 added 0 reduced 2 sold out vs Q1 2020

Options: 0 call positions (— notional), 1 put positions ($223.9m notional) – listed below, not included above.

Holdings, Q2 2020

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 DICERNA PHARMACEUTICALS INC COM DRNA DRNA 1,454,686 $36.9m13.58% 13.58% AddedShares held: Q4 2019 614.4k, Q1 2020 1.2m, Q2 2020 1.5m +217.3k +217,307 17.6%
2 ANAPTYSBIO INC COM ANAB ANAB 1,590,733 $35.5m13.06% 13.06% AddedShares held: Q4 2019 0, Q1 2020 1.4m, Q2 2020 1.6m +151.7k +151,654 10.5%
3 UNIQURE NV SHS QURE QURE 679,620 $30.6m11.26% 11.26% AddedShares held: Q4 2019 396.9k, Q1 2020 502.0k, Q2 2020 679.6k +177.6k +177,645 35.4%
4 SPERO THERAPEUTICS INC COM SPRO SPRO 1,943,081 $26.3m9.66% 9.66% AddedShares held: Q4 2019 1.2m, Q1 2020 1.8m, Q2 2020 1.9m +124.9k +124,941 6.9%
5 BLUEPRINT MEDICINES CORP COM BPMC BPMC 315,029 $24.6m9.03% 9.03% NewShares held: Q4 2019 0, Q1 2020 0, Q2 2020 315.0k
6 ARROWHEAD PHARMACEUTICALS IN COM ARWR ARWR 563,291 $24.3m8.94% 8.94% AddedShares held: Q4 2019 0, Q1 2020 436.5k, Q2 2020 563.3k +126.8k +126,777 29.0%
7 NGM BIOPHARMACEUTICALS INC COM NGM NGM 1,095,184 $21.6m7.95% 7.95% AddedShares held: Q4 2019 0, Q1 2020 1.0m, Q2 2020 1.1m +48.0k +48,000 4.6%
8 REGENXBIO INC COM RGNX RGNX 553,453 $20.4m7.49% 7.49% AddedShares held: Q4 2019 268.8k, Q1 2020 273.2k, Q2 2020 553.5k +280.2k +280,242 102.6%
9 PIERIS PHARMACEUTICALS INC COM COM 5,575,530 $17.3m6.35% 6.35% UnchangedShares held: Q4 2019 5.0m, Q1 2020 5.6m, Q2 2020 5.6m
10 PROQR THRAPEUTICS N V SHS EURO PRQR PRQR 2,401,570 $14.6m5.37% 5.37% UnchangedShares held: Q4 2019 1.9m, Q1 2020 2.4m, Q2 2020 2.4m
11 GALAPAGOS NV SPON ADR LKFT LKFT 44,234 $8.7m3.21% 3.21% UnchangedShares held: Q4 2019 72.0k, Q1 2020 44.2k, Q2 2020 44.2k
12 ARGENX SE SPONSORED ADR ARGX ARGX 35,800 $8.1m2.96% 2.96% NewShares held: Q4 2019 0, Q1 2020 0, Q2 2020 35.8k
13 MORPHOSYS AG SPONSORED ADS SPONSORED ADS 95,898 $3.0m1.12% 1.12% UnchangedShares held: Q4 2019 6.1k, Q1 2020 95.9k, Q2 2020 95.9k

Sold out since Q1 2020

SecurityTickerShares held beforeValue then
XENON PHARMACEUTICALS INC XENE XENE 1,499,970 $17.0m1.5m shares
MERUS N V MRUS MRUS 770,183 $9.3m770.2k shares

Options (notional value)

UnderlyingTickerTypeShares controlled NotionalChange
SPDR SER TR XBI · Put XBIPut 2,000,000 $223.9m2.0m shares Added